NCT04530864View on ClinicalTrials.gov

Pre-Surgical Ocular Surface Treatment With Intracanalicular Dexamethasone Insert And Effect On Intraocular Lens Measurement Accuracy

PHASE4UnknownINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

January 31, 2021

Primary Completion Date

January 31, 2021

Study Completion Date

July 31, 2021

Conditions

Dry Eye DiseaseCataract SurgeryOcular Surface Disease

Interventions

DRUG

Dextenza 0.4Mg Ophthalmic Insert

All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg

Sponsors

Collaborators (1)

Ocular Therapeutix, Inc.

All Listed Sponsors

collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Prism Vision Group

OTHER